Brought to you by 
Caelum Biosciences gets amyloidosis candidate from Columbia University
31 Jan 2019
Executive Summary
Caelum Biosciences Inc., the newly established (and eighth) subsidiary of Fortress Biotech Inc., licensed exclusive global rights to CAEL101, a monoclonal antibody in Phase I for amyloid light chain (AL) amyloidosis, from Columbia University. Financial terms were not disclosed.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Caelum Biosciences gets amyloidosis candidate from Columbia University
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice